Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verastem Inc VSTM

Healthcare Biotechnology
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more

Recent & Breaking News (NDAQ:VSTM)

Verastem Reports Year-End 2012 Financial Results

Business Wire March 27, 2013

Verastem Announces Timing for Year-End 2012 Financial Results, Webcast and Conference Call

Business Wire March 13, 2013

Stephen Sherwin, M.D., Joins Verastem Board of Directors

Business Wire March 6, 2013

Verastem Cofounders to Present at MIT Technology Breakfast on Breakthrough Discoveries in Cancer Stem Cells

Business Wire February 27, 2013

Verastem to Present at Upcoming Conferences

Business Wire February 26, 2013

Verastem Files for Orphan Disease Status for VS-6063 in Mesothelioma

Business Wire February 14, 2013

Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics

Business Wire February 6, 2013

Verastem Initiates Phase 1/1b Clinical Trial of VS-6063 Plus Paclitaxel for Patients with Ovarian Cancer

Business Wire February 5, 2013

Verastem to Present at Upcoming Conferences

Business Wire February 4, 2013

Verastem Promotes Chief Operating Officer Robert Forrester to President

Business Wire January 22, 2013

For Bessemer Venture Partners 2012 Proved a Banner Year: Highlights Include Five IPOs, Major M&A Exits, and 20 New Investments

Marketwired January 17, 2013

Verastem Enters Biomarker Agreement with LabCorp for Cancer Stem Cell Agent Companion Diagnostic

Business Wire January 9, 2013

Verastem to Present at East/West CEO and J.P. Morgan Healthcare Conferences

Business Wire January 3, 2013